← Back to Search

Dietary Supplement

Omega 3, Vitamins A, D3 and E for Dry Eye Syndrome (ONIT Trial)

Phase 4
Waitlist Available
Led By Sean Mulqueeny, OD
Research Sponsored by Eye and Vision Technologies and Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18 to 79 at the time of informed consent.
Must understand; be willing and able, and likely to fully comply with study procedures, visit schedule, and restrictions.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up two months
Awards & highlights

ONIT Trial Summary

Dry eye disease (DED) is a common but often inadequately treated disease of the tears and surface of the eye. It can cause poor vision and chronic pain and is more frequent with increasing age. The 1995 Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eye defined dry eye as "a disorder of the tear film due to tear deficiency or excessive evaporation, which causes damage to the interpalpebral ocular surface and is associated with symptoms of ocular discomfort". The International Dry Eye Work Shop (DEWS) committee subsequently defined dry eye as "a multi-factorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface." Typically, symptoms associated with dry eye disease include ocular burning, foreign body sensation (sand or grit), photophobia (light sensitivity), and other symptoms that result in overall long term discomfort in patients. The proposed eight week feasibility study if dry eye subjects confirmed elevated osmolarity and symptoms respond to nutritional therapy.

Eligible Conditions
  • Dry Eye Syndrome

ONIT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

ONIT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~two months
This trial's timeline: 3 weeks for screening, Varies for treatment, and two months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dry eye subjects ingesting omega three and the effect on seven diagnostic markers responding to omega 3 nutritional therapy.

ONIT Trial Design

1Treatment groups
Experimental Treatment
Group I: Omega 3, Vitamins A, D3 and EExperimental Treatment1 Intervention
Dry eye patients that have been screened with elevated osmolarity dispensed EZ Tears supplements containing Omega 3, Vitamins A, D3 and E to evaluate the change in dry eye conditions subjectively and objectively.

Find a Location

Who is running the clinical trial?

ZeaVision, Inc.Industry Sponsor
2 Previous Clinical Trials
213 Total Patients Enrolled
Eye and Vision Technologies and Research InstituteLead Sponsor
Sean Mulqueeny, ODPrincipal Investigator

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~6 spots leftby Mar 2025